KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATFurniture, Fixtures and OtherLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares IssuedShort-Term Debt repayments
Ratios

Boston Scientific (BSX) EBIAT (2016 - 2025)

Boston Scientific (BSX) has disclosed EBIAT for 17 consecutive years, with $670.0 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 19.22% to $670.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Dec 2025, up 56.75% year-over-year, with the annual reading at $2.9 billion for FY2025, 56.66% up from the prior year.
  • EBIAT hit $670.0 million in Q4 2025 for Boston Scientific, down from $755.0 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $795.0 million in Q2 2025 to a low of $95.0 million in Q4 2021.
  • Historically, EBIAT has averaged $403.4 million across 5 years, with a median of $380.0 million in 2021.
  • Biggest five-year swings in EBIAT: skyrocketed 3000.0% in 2021 and later tumbled 67.74% in 2022.
  • Year by year, EBIAT stood at $95.0 million in 2021, then skyrocketed by 47.37% to $140.0 million in 2022, then surged by 260.0% to $504.0 million in 2023, then grew by 11.51% to $562.0 million in 2024, then rose by 19.22% to $670.0 million in 2025.
  • Business Quant data shows EBIAT for BSX at $670.0 million in Q4 2025, $755.0 million in Q3 2025, and $795.0 million in Q2 2025.